HS830 Unit 9 Anti-Amyloid Treatment Position Paper Example

Build the Pathway Before the Infusion Chair: A Unit 9 Position Paper on Anti-Amyloid Alzheimer's Treatment at a Community Hospital

[Student Name]

Purdue University Global

HS830: Advanced Health Issues and Trends

Unit 9 Position Paper

[Instructor Name]

[Date]

The hospital, its neurology group and its figures are composite; the trials, approvals and coverage rules cited are real.

Position

The hospital should build, over the next twelve months, the three capabilities any anti-amyloid program depends on: a memory assessment pathway that confirms early Alzheimer's disease and amyloid status, an MRI protocol and reading service for amyloid-related imaging abnormalities (ARIA), and a referral partnership with the academic center ninety miles away for infusion and complication management. It should open its own infusion service only when confirmed eligible patients in its region reach a stated volume.

Background

Lecanemab received traditional FDA approval in July 2023, and donanemab in July 2024, both for early symptomatic Alzheimer's disease, meaning the mild cognitive impairment or mild dementia stage, once amyloid is confirmed. In the lecanemab phase 3 trial, the drug slowed decline by 0.45 points over 18 months on the Sum of Boxes score of the Clinical Dementia Rating, about 27 percent less decline than placebo; ARIA with edema occurred in 12.6 percent of treated participants against 1.7 percent on placebo (van Dyck et al., 2023). In the donanemab trial, decline slowed by about a third on the primary measure, and ARIA with edema occurred in about 24 percent of treated participants, with three deaths judged related to treatment (Sims et al., 2023).

Medicare covers both drugs when the treating clinician enrolls the patient in a national registry, under a coverage with evidence development policy. Treatment requires confirming amyloid with PET or cerebrospinal fluid testing, a baseline MRI and repeated MRIs during the first months, counseling about APOE e4 status because carriers face higher ARIA risk, and infusions every two or four weeks. Appropriate use recommendations published soon after approval set out these steps in detail, including MRI before the fifth, seventh and fourteenth lecanemab infusions and rules for pausing or stopping treatment when ARIA appears (Cummings et al., 2023). Each step needs staff, scanner time and neurologists able to act on what the scans show.

The hospital's own position frames the decision. It employs three general neurologists and no cognitive specialist. Its two MRI scanners run at about 85 percent capacity. Its outpatient infusion center is full four days a week. In the past year, primary care clinicians referred about 140 patients for memory concerns, and the neurology group estimates that perhaps one in ten would meet the trials' criteria after testing.

The Three Options

Each option is judged on the same criteria: clinical benefit and safety, financial exposure, policy and evidence risk, and reversibility.

Launch now. Clinical benefit: real but modest, measured in months of slowed decline. Safety: ARIA is usually asymptomatic but can be serious, and managing it requires neurologists experienced in reading surveillance scans and deciding when to pause treatment. Financial exposure: moderate, since Medicare pays for the drug and infusion, but the hospital would carry the cost of new staff, scanner hours and training before volume arrives. Policy and evidence risk: the registry requirement and long-term outcome data could change the economics either way. Reversibility: poor. Patients who start treatment need continued monitoring, and closing a program midstream would leave them stranded.

Wait. Clinical benefit: lost for the small number of eligible patients who could have been treated locally, though they can travel to the academic center. Financial exposure: none now. Policy and evidence risk: low. Reversibility: high. The hidden cost is that the hospital would still be unable to diagnose early Alzheimer's disease accurately, which matters for patients whether or not they receive the new drugs, and it would fall further behind as blood-based amyloid tests and simpler dosing arrive.

Prepare. The hospital builds the three capabilities named in the position and refers eligible patients to the academic center for infusion. Clinical benefit: patients are diagnosed earlier and more accurately, and those eligible reach treatment sooner. Financial exposure: modest, mostly a part-time cognitive nurse navigator, neuroradiology training and protocol work. Policy and evidence risk: low, because diagnostic capacity keeps its value under any coverage decision. Reversibility: high.

The scarce resource in this decision is not the infusion chair; it is the ability to find the right patients and to read their scans safely, and that ability is worth building whatever happens to the drugs.

Why Preparing Wins Now

If the drugs had large benefits and simple monitoring, launching now would be right. If the evidence were doubtful, waiting would be right. Neither describes the situation. The benefit is real but modest, and safe use depends on diagnostic and imaging capacity the hospital does not have. Preparing builds exactly that capacity, which also improves care for the much larger number of patients with memory concerns who will never be eligible. With an estimated fourteen eligible patients a year, the hospital could not yet sustain the expertise needed to manage ARIA locally, while the academic center already manages it at volume.

The weakest part of the preparing option is travel. A ninety-mile trip every two or four weeks is a real burden for older patients and their caregivers, and some will decline treatment rather than make it. The paper therefore asks the hospital to negotiate a shared-care arrangement in which the academic center starts treatment and manages early surveillance while the hospital performs later MRIs locally, using the protocol and reading service it is building.

How the Evidence Should Be Read

Trial participants were carefully selected, with fewer coexisting conditions than typical community patients, and the trials excluded people with significant vascular brain disease, which is common in older adults. Real-world rates of ARIA and discontinuation may differ. The clinical meaning of the measured slowing is debated, since the difference on the rating scale is small relative to the scale's range. These are reasons to build a pathway that selects patients carefully, not reasons to deny the treatment to people who meet the criteria and choose it after counseling.

The Trigger

The hospital should open its own infusion service when either of two things happens. First, if confirmed eligible patients in its region reach thirty a year for two consecutive years, enough to sustain a trained team. Second, if approved dosing becomes simpler, for example through subcutaneous maintenance that reduces infusion visits, or if blood-based amyloid testing makes confirmation substantially cheaper and faster. When either trigger is met, the neurology group should present a staffing and imaging plan to the executive team within ninety days.

Conclusion

Opening an infusion service now would commit scarce scanner time and neurologist attention to a small number of patients before the hospital could manage the drugs' main risk. Waiting would leave the hospital unable to diagnose early Alzheimer's disease well. Preparing builds the diagnostic, imaging and referral capacity that every path requires, serves eligible patients through a partner today, and sets a clear point at which the hospital takes treatment in-house.

References

Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S. (2023). Lecanemab: Appropriate use recommendations. The Journal of Prevention of Alzheimer's Disease, 10(3), 362-377. https://doi.org/10.14283/jpad.2023.30

Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., Collins, E. C., Solomon, P., Salloway, S., Apostolova, L. G., Hansson, O., Ritchie, C., Brooks, D. A., Mintun, M., & Skovronsky, D. M. (2023). Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA, 330(6), 512-527. https://doi.org/10.1001/jama.2023.13239

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in early Alzheimer's disease. New England Journal of Medicine, 388(1), 9-21. https://doi.org/10.1056/NEJMoa2212948